OR WAIT 15 SECS
The Basel office will house the clinical development team and other functions to progress the company’s lead compound emapalumab.
Swiss biotech company, Novimmune, has opened a branch office in Basel, Switzerland. Novimmune specializes in the development of antibody-based drugs. The Basel office at Dufourstrasse 11 will house the clinical development team and other functions to progress the company’s lead compound emapalumab. Novimmune is working towards a regulatory filing for marketing authorization and hopes to launch the product in Europe and the United States.
Emapalumab (NI-0501) is currently undergoing phase 2/3 evalution for the treatment of primary hemophagocytic lymphohistiocytosis, a life-threatening disease of severe hyperinflammation, which mainly affects children. In June 2016, the drug was granted priority medicine status by the European Medicines Agency (EMA), just three months after the US Food and Drug Administration (FDA) had approved its breakthrough therapy designation.